Amgen teams with Immatics on cancer immunotherapies
Amgen will manufacture, trial and sell cancer immunotherapies developed in collaboration with Immatics Biotechnologies GmbH under an agreement announced this week.
Archives for January 11, 2017
Teva aiming to be major second and third wave biosimilars company
Teva: ‘Celltrion deal will double biosimilar sales to $600m’
Celltrion deal and multi-million Euro German plant will make it a major second and third wave biosimilars player says Teva.
AGC boasts 44,000L of biomanufacturing capacity on back of recent M&A
After buying two CMOs, Japanese glassmaker AGC has made “a full-fledged launch” into the biologics manufacturing space and says it will consider further M&A opportunities.